沙美特罗替卡松联合噻托溴铵治疗COPD的疗效

Salmeterol and fluticasone propionate combined tiotropium in chronic obstructive pulmonary disease,the efficacy analysis

目的观察沙美特罗替卡松联合噻托溴铵治疗慢性阻塞性肺疾病(COPD)的疗效。方法入选的60例COPD患者随机分为观察组和对照组,两组各30例。对照组采用沙美特罗替卡松(舒利迭,50/500μg,英国葛兰素史克公司生产)治疗;观察组联合应用噻托溴铵(思力华,18μg/粒,德国勃林格殷格翰药业有限公司)。结果治疗6个月后,观察组的临床症状评分为(7.2±2.3)分,对照组为(4.0±1.6)分,两组比较差异显著(P<0.05)。观察组的总有效率(93.33%)明显高于对照组(73.33%),差异具有统计学意义(P<0.05)。两组患者均未见明显的不良反应。结论沙美特罗替卡松联合噻托溴铵治疗慢性阻塞性肺疾病(COPD)的疗效确切,能明显改善临床症状,安全性好,值得广泛推广和应用。

Objective To observe the combined salmeterol and fluticasone propionate with tiotropium in chronic obstructive pulmonary disease （COPD）. Methods All of 60 selected patients with COPD were randomly divided into two groups and the control group of 30 cases. Both groups were symptomatic with normal oxygen and other nutrients to support treatment, while the control group using salmeterol and fluticasone propionate （Seretide, 50/500 μg, the British company Glaxo- SmithKline） treatment; observation group were based the combination of tiotropium （Spiriva, 18 μg / tablets, Boehringer Ingelheim Pharmaceutical Co. Ltd.）. Results After 6 months, the clinical symptoms observed group score （7.2±2.3） points, the control group was （4.0±1.6） points, the difference was significant （P 〈 0.05）. The total effective observation group （93.33%） was significantly higher （73.33%）, significant difference （P 〈 0.05）. All patients were no significant adverse reactions. Conclusion Salmeterol and fluticasone propionate combined tiotropium in chronic obstructive pulmonary disease （COPD） the effective, can significantly improve the clinical symptoms, safety, and worthy of extensive promotion and application.